| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.3 | 0.0 |
| Net income | -49.2 | -45.5 |
| EPS (diluted, $ a share) | $-0.50 | $-0.87 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: INO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Inovio Pharmaceuticals, Inc.: key numbers
- Share price
- $1.63Close, Nov 17
- Market cap
- $305M
- Shares outstanding
- 187.31MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Inovio Pharmaceuticals, Inc.
All →Inovio Pharmaceuticals Leadership Change
Inovio Pharmaceuticals appointed Jeffrey Libson to its Board of Directors, effective November 13, 2026, increasing the board size from eight to nine members. Mr. Libson, a former partner at Cooley LLP with extensive life sciences legal and strategic experience, will also serve on the company's Finance Committee. He will receive an annual cash retainer of $45,000 for his board service plus $5,000 for his committee role under the company's non-employee director compensation program.
Inovio Pharmaceuticals Financial Results
INOVIO reported Q3 2026 financial results and highlighted the landmark FDA accelerated approval of VOCERYQ, the first-ever approved DNA medicine, for the treatment of Recurrent Respiratory Papillomatosis (RRP). The company recently completed a public offering raising $80.5 million in net proceeds to support the commercial launch of VOCERYQ, which is expected to be available for order in early 2027.
“We are delighted with the recent approval of VOCERYQ, which FDA described as a groundbreaking therapy that fights RRP at its source, not only its symptoms. INOVIO is now a commercial stage company with a primary goal to establish VOCERYQ as the preferred first-line immunotherapy for RRP patients.”
Dr. Jacqueline Shea, INOVIO’s President and Chief Executive Officer
“Our recently completed public offering provides additional financial resources to support a successful launch. Furthermore, this approval validates our DNA medicine platform and we are actively seeking partnerships to accelerate the development of other exciting candidates within our pipeline”
Dr. Jacqueline Shea, INOVIO’s President and Chief Executive Officer
Inovio Pharmaceuticals Capital Raise of $80.5M
INOVIO Pharmaceuticals entered into an underwriting agreement for a public offering of 58,747,235 shares of common stock and 12,681,337 pre-funded warrants. The underwriters fully exercised their option to purchase an additional 10,714,285 shares, bringing expected net proceeds to approximately $80.5 million. The capital will be used to support the company's development and commercialization of DNA medicines.
- Value
- $80.5M
- Counterparty
- Jefferies LLC and Piper Sandler & Co.
Inovio Pharmaceuticals Business Update
INOVIO Pharmaceuticals provided a preliminary financial update for the quarter ended September 30, 2026, estimating its cash, cash equivalents, and short-term investments at approximately $48.4 million. This disclosure serves as a selective operational update ahead of its full quarterly financial report.
- Term
- Q3 2026
Inovio Pharmaceuticals Regulatory Approval
The FDA granted accelerated approval for INOVIO's VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) to reduce the frequency of surgery in adults with Recurrent Respiratory Papillomatosis (RRP). This represents the first U.S. FDA-approved DNA medicine and validates INOVIO's platform technology, with a commercial launch expected in Q1 2027.
“With the approval of VOCERYQ, we believe our DNA medicine platform has the potential to transform the treatment paradigm for RRP by offering a patient-centric treatment option. VOCERYQ is designed to deliver what we understand matters most to patients, which is the reduction of the surgical burden caused by RRP.”
Dr. Jacqueline Shea, INOVIO’s President and Chief Executive Officer